Susquehanna International Group, LLP Atossa Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.09 - $1.52 $19,729 - $27,512	18,100 Added 34.15%	71,100 $108,000
Q2 2024 Aug 15, 2024	BUY	$1.03 - $2.1 $27,295 - $55,650	26,500 Added 100.0%	53,000 $63,000
Q1 2024 May 07, 2024	BUY	$0.8 - $1.89 $21,200 - $50,085	26,500 New	26,500 $47,000
Q3 2023 Nov 14, 2023	BUY	$0.74 - $1.35 $23,606 - $43,065	31,900 New	31,900 $23,000
Q1 2023 May 16, 2023	SELL	$0.59 - $0.91 $3,894 - $6,006	-6,600 Reduced 25.48%	19,300 $13,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $66,150 - $133,623	-132,300 Reduced 83.63%	25,900 $13,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $29,520 - $41,040	-36,000 Reduced 18.54%	158,200 $131,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.